The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...
Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback